{"id":"W2088164570","doi":"10.3810/pgm.2014.10.2821","title":"Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes","year":2014,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada); Hôtel-Dieu de Montréal","funders":"Eli Lilly and Company","keywords":"Dulaglutide; Medicine; Exenatide; Metformin; Type 2 diabetes; Glucagon-like peptide 1 receptor; Glycemic; Sitagliptin; Liraglutide; Internal medicine; Nausea; Hypoglycemia; Clinical endpoint; Pharmacology; Diabetes mellitus; Insulin; Endocrinology; Clinical trial; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005445095,0.0003530856,0.002108633,0.002103246,0.0002283921,0.001255638,0.0005883698,0.001196551,0.002373009],"category_scores_gemma":[0.01187855,0.0001849004,0.002450204,0.001672135,0.0003404162,0.001002568,0.0003012938,0.0009228218,0.0004484447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00062553,"about_ca_system_score_gemma":0.001517893,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004242292,"about_ca_topic_score_gemma":0.001009481,"domain_scores_codex":[0.9970865,0.0012131,0.0008228089,0.0002525431,0.0005528523,0.00007225304],"domain_scores_gemma":[0.9908202,0.003855142,0.00342829,0.0001437395,0.001498279,0.0002543114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04429575,0.0006445781,0.005849614,0.1635489,0.006439467,0.001027609,0.0002592407,0.0004195565,0.009000696,0.0006152827,0.007084053,0.7608152],"study_design_scores_gemma":[0.051659,0.1448676,0.1132683,0.2828413,0.09043381,0.01450213,0.00193068,0.002111234,0.02128924,0.003137862,0.2734844,0.0004746306],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01256653,0.9845998,0.0001449436,0.0006632264,0.0002407837,0.00009857796,0.0002862596,0.000008718647,0.001391083],"genre_scores_gemma":[0.1825451,0.8120484,0.001041634,0.001990682,0.000944111,0.0002649341,0.0006322046,0.00001494518,0.0005179477],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005445095,"threshold_uncertainty_score":0.02879673,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03907160391263062,"score_gpt":0.3232018956930605,"score_spread":0.2841302917804298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}